Develops precision medicines for neurodegenerative diseases by targeting dysregulated palmitoylation and synaptic dysfunction, with a focus on CLN1 Batten Disease. By leveraging high-fidelity animal models and insights into protein localization, lysosomal function, and autophagy, Circumvent aims to create disease-modifying treatments that address the underlying mechanisms of multiple neurological disorders.
Funding
$7.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DFHPTLFounders
Product
Problem
Neurodegenerative diseases, including CLN1 Batten Disease, present a significant unmet need due to the lack of effective, disease-modifying treatments. Current therapeutic development is hindered by limited understanding of the underlying disease mechanisms and the absence of predictive animal models. Specifically, CLN1 Batten Disease results from a mutation in the CLN1 gene, leading to the accumulation of palmitate on proteins and subsequent neurodegeneration.
Solution
Circumvent Pharmaceuticals is developing precision medicines for neurodegenerative diseases by targeting dysregulated palmitoylation and synaptic dysfunction. The company leverages high-fidelity animal models and insights into protein localization, lysosomal function, and autophagy to create treatments that address the root causes of neurological disorders. Circumvent's approach focuses on modulating the palmitoylome and synaptome to restore synaptic plasticity and neuronal differentiation. Their research aims to characterize the palmitoylome with precision and investigate therapeutic strategies for modulating it, offering potential medicines for both rare and common forms of neurodegenerative disease.
Target Audience
The primary target audience includes patients with rare neurological diseases like CLN1 Batten Disease, their caregivers, and clinicians specializing in neurodegenerative disorders.
Features
- Focus on CLN1 Batten Disease, a severe form of Batten Disease caused by mutations in the CLN1 gene
- Utilizes high-fidelity, predictive animal models for preclinical development
- Targets dysregulated palmitoylation, a key mechanism in neurodegeneration
- Investigates the synaptome and its effect on synaptic function
- Explores therapeutic strategies for modulating the palmitoylome
- Aims to restore synaptic plasticity and neuronal differentiation